Review of major clinical trial with mycophenolate mofetil in renal transplantation

Gaetano Ciancio, Joshua Miller, Thomas A. Gonwa

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Mycophenolate mofetil (MMF) was approved for the prevention of acute rejection following renal transplantation based on the results of three groundbreaking, large, clinical trials that demonstrated a significantly reduced risk of acute rejection in patients receiving MMF when compared with those receiving placebo or azathioprine. These three multicenter, prospective, double-blind trials performed at 55 transplant centers on three continents were the largest immunosuppressive drug trials ever attempted and the first prospective, randomized, double-blind trials ever performed in transplantation. These pivotal trials established a foundation for widespread acceptance of MMF in combination with cyclosporine and steroids as a maintenance regimen for renal transplant patients. The findings of these initial trials that led to the approval of MMF for renal transplantation, including long-term follow-up data, will be reviewed in this paper. The expanding scope of major trials of MMF, including trials in pediatric patients, combination regimens with novel induction therapies or other maintenance agents, and trials in special patient populations such as those at high immunological risk or with deteriorating kidney function, will also be discussed.

Original languageEnglish
JournalTransplantation
Volume80
Issue numberSUPPL. 2
DOIs
StatePublished - Oct 15 2005

Fingerprint

Mycophenolic Acid
Kidney Transplantation
Clinical Trials
Maintenance
Transplants
Kidney
Azathioprine
Immunosuppressive Agents
Cyclosporine
Transplantation
Steroids
Placebos
Pediatrics
Pharmaceutical Preparations
Population

Keywords

  • Immunosuppression
  • Mycophenolate mofetil
  • Rejection
  • Renal transplantation

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Review of major clinical trial with mycophenolate mofetil in renal transplantation. / Ciancio, Gaetano; Miller, Joshua; Gonwa, Thomas A.

In: Transplantation, Vol. 80, No. SUPPL. 2, 15.10.2005.

Research output: Contribution to journalArticle

Ciancio, Gaetano ; Miller, Joshua ; Gonwa, Thomas A. / Review of major clinical trial with mycophenolate mofetil in renal transplantation. In: Transplantation. 2005 ; Vol. 80, No. SUPPL. 2.
@article{9fd098068cfa42efbe14141dd458d9f5,
title = "Review of major clinical trial with mycophenolate mofetil in renal transplantation",
abstract = "Mycophenolate mofetil (MMF) was approved for the prevention of acute rejection following renal transplantation based on the results of three groundbreaking, large, clinical trials that demonstrated a significantly reduced risk of acute rejection in patients receiving MMF when compared with those receiving placebo or azathioprine. These three multicenter, prospective, double-blind trials performed at 55 transplant centers on three continents were the largest immunosuppressive drug trials ever attempted and the first prospective, randomized, double-blind trials ever performed in transplantation. These pivotal trials established a foundation for widespread acceptance of MMF in combination with cyclosporine and steroids as a maintenance regimen for renal transplant patients. The findings of these initial trials that led to the approval of MMF for renal transplantation, including long-term follow-up data, will be reviewed in this paper. The expanding scope of major trials of MMF, including trials in pediatric patients, combination regimens with novel induction therapies or other maintenance agents, and trials in special patient populations such as those at high immunological risk or with deteriorating kidney function, will also be discussed.",
keywords = "Immunosuppression, Mycophenolate mofetil, Rejection, Renal transplantation",
author = "Gaetano Ciancio and Joshua Miller and Gonwa, {Thomas A.}",
year = "2005",
month = "10",
day = "15",
doi = "10.1097/01.tp.0000187035.22298.ba",
language = "English",
volume = "80",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Review of major clinical trial with mycophenolate mofetil in renal transplantation

AU - Ciancio, Gaetano

AU - Miller, Joshua

AU - Gonwa, Thomas A.

PY - 2005/10/15

Y1 - 2005/10/15

N2 - Mycophenolate mofetil (MMF) was approved for the prevention of acute rejection following renal transplantation based on the results of three groundbreaking, large, clinical trials that demonstrated a significantly reduced risk of acute rejection in patients receiving MMF when compared with those receiving placebo or azathioprine. These three multicenter, prospective, double-blind trials performed at 55 transplant centers on three continents were the largest immunosuppressive drug trials ever attempted and the first prospective, randomized, double-blind trials ever performed in transplantation. These pivotal trials established a foundation for widespread acceptance of MMF in combination with cyclosporine and steroids as a maintenance regimen for renal transplant patients. The findings of these initial trials that led to the approval of MMF for renal transplantation, including long-term follow-up data, will be reviewed in this paper. The expanding scope of major trials of MMF, including trials in pediatric patients, combination regimens with novel induction therapies or other maintenance agents, and trials in special patient populations such as those at high immunological risk or with deteriorating kidney function, will also be discussed.

AB - Mycophenolate mofetil (MMF) was approved for the prevention of acute rejection following renal transplantation based on the results of three groundbreaking, large, clinical trials that demonstrated a significantly reduced risk of acute rejection in patients receiving MMF when compared with those receiving placebo or azathioprine. These three multicenter, prospective, double-blind trials performed at 55 transplant centers on three continents were the largest immunosuppressive drug trials ever attempted and the first prospective, randomized, double-blind trials ever performed in transplantation. These pivotal trials established a foundation for widespread acceptance of MMF in combination with cyclosporine and steroids as a maintenance regimen for renal transplant patients. The findings of these initial trials that led to the approval of MMF for renal transplantation, including long-term follow-up data, will be reviewed in this paper. The expanding scope of major trials of MMF, including trials in pediatric patients, combination regimens with novel induction therapies or other maintenance agents, and trials in special patient populations such as those at high immunological risk or with deteriorating kidney function, will also be discussed.

KW - Immunosuppression

KW - Mycophenolate mofetil

KW - Rejection

KW - Renal transplantation

UR - http://www.scopus.com/inward/record.url?scp=27644535270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644535270&partnerID=8YFLogxK

U2 - 10.1097/01.tp.0000187035.22298.ba

DO - 10.1097/01.tp.0000187035.22298.ba

M3 - Article

C2 - 16251852

AN - SCOPUS:27644535270

VL - 80

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - SUPPL. 2

ER -